A Study To Investigate The Absorption, Metabolism And Excretion Of [14C] PD 0200390 In Six Healthy Male Volunteers

Phase 1CompletedNCT00722306

Pfizer6 enrolled

Overview

To determine the mass balance of PD 0200390

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Healthy Exclusion Criteria: * unhealthy, or concomitant meds

Pfizer Investigational Site

New Haven, Connecticut, United States

Radioactivity parameters in plasma and whole blood - Cmax , Tmax , AUCinf, AUClast, t1/2, CL/F and V/F and Total 14C data in blood, urine and feces

Time frame: 2 days

% urinary recovery

Time frame: 2 days

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.